Advertisement
UK markets close in 2 hours 44 minutes

  • FTSE 100

    7,862.58
    -102.95 (-1.29%)
     

  • FTSE 250

    19,444.45
    -254.44 (-1.29%)
     

  • AIM

    742.09
    -8.19 (-1.09%)
     

  • GBP/EUR

    1.1708
    -0.0003 (-0.03%)
     

  • GBP/USD

    1.2469
    +0.0023 (+0.18%)
     

  • Bitcoin GBP

    50,650.15
    -2,461.70 (-4.63%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • S&P 500

    5,061.82
    -61.59 (-1.20%)
     

  • DOW

    37,735.11
    -248.13 (-0.65%)
     

  • CRUDE OIL

    85.09
    -0.32 (-0.37%)
     

  • GOLD FUTURES

    2,390.20
    +7.20 (+0.30%)
     

  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     

  • HANG SENG

    16,248.97
    -351.49 (-2.12%)
     

  • DAX

    17,826.36
    -200.22 (-1.11%)
     

  • CAC 40

    7,959.05
    -86.06 (-1.07%)
     
Money:

How to avoid tax creep in retirement

The state pension went up 8.5% in April, but frozen thresholds mean pensioners will be paying more tax

Pharvaris to Participate in H.C. Wainwright 1st Annual Hereditary Angioedema (HAE) Conference

Pharvaris N.V.
·1-min read
Pharvaris N.V.
Pharvaris N.V.

ZUG, Switzerland, July 14, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today announced that management will participate in a fireside chat at the H.C. Wainwright 1st Annual Hereditary Angioedema (HAE) Conference taking place virtually on July 20, 2022.

Pharvaris’ fireside chat will take place at 1:30 PM EDT (7:30 PM CEST) on Wednesday, July 20, 2022. A live webcast of the presentation will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations. A replay will be available on Pharvaris’ website for 30 days following the presentation.

About Pharvaris
Pharvaris is a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in HAE. By directly targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE more effective and convenient alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit https://pharvaris.com/

Contact
Maryann Cimino
Director of Corporate Relations
+1-617-710-7305
maryann.cimino@pharvaris.com